Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
- 20 June 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (14)
Abstract
Adeno-associated virus (AAV) vector liver-directed gene therapy (GT) for hemophilia B (HB) is limited by a vector dose–dependent hepatotoxicity. Recently, this obstacle has been partially circumvented by the use of a hyperactive factor IX (FIX) variant, R338L (Padua), which has an 8-fold increased specific activity compared with FIX-WT. FIX-R338L has emerged as the standard for HB GT. However, the underlying mechanism of its hyperactivity is undefined; as such, safety concerns of unregulated coagulation and the potential for thrombotic complications have not been fully addressed. To this end, we evaluated the enzymatic and clotting activity as well as the activation, inactivation, and cofactor dependence of FIX-R338L relative to FIX-WT. We observed that the high specific activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor. In a potentially novel system using emicizumab, an FVIII-mimicking bispecific antibody, the hyperactivity of both recombinant FIX-R338L and AAV-mediated transgene-expressed FIX-R338L from HB GT subjects was ablated without FVIIIa activity. We conclude that the molecular regulation of activation, inactivation, and cofactor dependence of FIX-R338L is similar to FIX-WT but that the FVIIIa-dependent hyperactivity of FIX-R338L is the result of a faster rate of factor X activation. This mechanism helps mitigate safety concerns of unregulated coagulation and supports the expanded use of FIX-R338L in HB therapy.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (P01HL64190)
- National Heart, Lung, and Blood Institute (P01HL139420)
- Pfizer (Aspire)
- National Heart, Lung, and Blood Institute (1K08HL140078)
- Hemostasis and Thrombosis Research Society (Mentored Research Award)
- Bayer Portugal (Bayer Hemophilia Program Fellowship Award)
This publication has 48 references indexed in Scilit:
- Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic miceBlood, 2012
- The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapyBlood, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- The Conformational Switch from the Factor X Zymogen to Protease State Mediates Exosite Expression and Prothrombinase AssemblyJournal of Biological Chemistry, 2008
- Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor XBlood, 2005
- The Factor IXa Heparin-Binding Exosite Is a Cofactor Interactive Site: Mechanism for Antithrombin-Independent Inhibition of Intrinsic Tenase by HeparinBiochemistry, 2005
- Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complexBlood, 2002
- Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.Journal of Clinical Investigation, 1993
- Activation of human factor IX (Christmas factor).Journal of Clinical Investigation, 1978
- An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical AmplifierNature, 1964